Medicinova
Clinical trials sponsored by Medicinova, explained in plain language.
-
New pill targets triple threat of fatty liver, diabetes, and blood fats
Disease control OngoingThis study is testing whether an oral medication called MN-001 can reduce liver fat and lower triglyceride levels in people who have non-alcoholic fatty liver disease, type 2 diabetes, and high triglycerides. About 40 participants will take either the study drug or a placebo pill…
Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for ALS patients: experimental drug aims to preserve muscle function
Disease control OngoingThis clinical trial is testing whether an experimental drug called MN-166 (ibudilast) can slow the progression of ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease). The study involves 234 adults recently diagnosed with ALS, who will take either the drug or a placebo for…
Phase: PHASE2, PHASE3 • Sponsor: MediciNova • Aim: Disease control
Last updated Mar 02, 2026 15:23 UTC